KYMR Live signals | Maximize Profits with Getagraph.com

BUY 101260 min ago

@ $36.93

Issued: 14 Feb 2024 @ 15:32

Return: -4.66%

Previous signal: Feb 14 - 09:30

Previous signal: Sell

Return: 3.50 %

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 16:00):

Stats
Today's Volume	335 676
Average Volume	657 096
Market Cap	2.15B
EPS	$0 ( 2024-02-22 )
Next earnings date	( $-0.720 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-13.97
ATR14	$0.0370 (0.11%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-28	Baker Bros. Advisors Lp	Buy	32 000	Non-Qualified Stock Option (right to buy)
2024-03-28	Baker Bros. Advisors Lp	Buy	0	Common Stock
2024-03-28	Baker Bros. Advisors Lp	Buy	0	Common Stock
2024-03-28	Baker Bros. Advisors Lp	Buy	7 379 066	Prefunded Warrants
2024-03-14	Booth Bruce	Sell	34 473	Common Stock

INSIDER POWER
44.26
Last 97 transactions
Buy: 2 823 290 \| Sell: 1 008 904

Volume Correlation

Long: -0.29 (neutral)

Short: -0.87 (strong negative)

Signal:(37.183) Neutral

Kymera Therapeutics, Inc. Correlation

10 Most Positive Correlations
GAIA	0.869
GPP	0.858
LIAN	0.857
GRNQ	0.854
DGRE	0.841
BATRK	0.836
AQMS	0.833
XBIT	0.833
WHLM	0.831
BNIXU	0.83

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Kymera Therapeutics, Inc. Correlation - Currency/Commodity

-0.07
( neutral )

-0.16
( neutral )

0.00
( neutral )

-0.21
( neutral )

0.63
( weak )

-0.02
( neutral )

Kymera Therapeutics, Inc. Financials

Annual	2023
Revenue:	$78.59M
Gross Profit:	$75.03M (95.46 %)
EPS:	$-2.52

Q4	2023
Revenue:	$47.89M
Gross Profit:	$47.02M (98.19 %)
EPS:	$-0.250

Q3	2023
Revenue:	$4.73M
Gross Profit:	$3.83M (80.96 %)
EPS:	$-0.900

Q2	2023
Revenue:	$16.51M
Gross Profit:	$15.61M (94.55 %)
EPS:	$-0.670

Financial Reports:

No articles found.

Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.